{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cusatis R"],"funding":["Takeda Pharmaceuticals U.S.A.","GlaxoSmithKline","Amgen","Bristol Myers Squibb Co.","CareDx","Actinium Pharmaceuticals","NHLBI NIH HHS","Pharmacyclics","MorphoSys","Adaptive Biotechnologies","Merck","Kiadis Pharma","Karyopharm Therapeutics","Novartis Pharmaceuticals Corporation","Sanofi Genzyme","National Cancer Institute","CytoSen Therapeutics","Kyowa Kirin","Seagen","Incyte","Medac","Accenture","Pfizer","Medical College of Wisconsin","Health Resources and Services Administration","AbbVie","Office of Naval Research","National Institute of Allergy and Infectious Diseases","Janssen Biotech","Miltenyi Biotec","Genentech","bluebird bio","Astellas Pharma US","Omeros Corporation","Be The Match Foundation","NCI NIH HHS","Daiichi Sankyo Co., Ltd.","Jazz Pharmaceuticals","Gilead","StemCyte"],"pagination":["229-250"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9839494"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["98(2)"],"pubmed_abstract":["For myelodysplastic syndrome (MDS), allogeneic hematopoietic cell transplantation (alloHCT) is the only available curative therapy. The Blood and Marrow Transplant Clinical Trials Network study 1102 (BMT CTN 1102, NCT02016781) was a multicenter, biologic assignment trial based on matched donor availability in adults aged 50-75 with higher risk de novo MDS who were candidates for reduced-intensity conditioning (RIC) alloHCT. The primary analysis showed that those who received alloHCT had a survival benefit, but whether this is at the cost of worse quality of life (QOL) has not been described in detail. English- and Spanish-speaking trial participants completed the Functional Assessment of Cancer Therapy-General (FACT-G), the SF-36, and the EQ-5D, at enrollment, every 6 months until 24 month"],"journal":["American journal of hematology"],"pubmed_title":["Health-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102."],"pmcid":["PMC9839494"],"funding_grant_id":["U24 HL138660","U10 HL069294","UG1 HL069246","U24HL138660","U24 CA076518","U24CA076518","U10HL069294"],"pubmed_authors":["Gregory A","Lee SJ","Logan BR","Saber W","Cusatis R","Flynn KE","D'Souza A","Hamilton BK","Cutler CS","Shaw BE","Martens MJ","Horowitz MM","Nakamura R"],"additional_accession":[]},"is_claimable":false,"name":"Health-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102.","description":"For myelodysplastic syndrome (MDS), allogeneic hematopoietic cell transplantation (alloHCT) is the only available curative therapy. The Blood and Marrow Transplant Clinical Trials Network study 1102 (BMT CTN 1102, NCT02016781) was a multicenter, biologic assignment trial based on matched donor availability in adults aged 50-75 with higher risk de novo MDS who were candidates for reduced-intensity conditioning (RIC) alloHCT. The primary analysis showed that those who received alloHCT had a survival benefit, but whether this is at the cost of worse quality of life (QOL) has not been described in detail. English- and Spanish-speaking trial participants completed the Functional Assessment of Cancer Therapy-General (FACT-G), the SF-36, and the EQ-5D, at enrollment, every 6 months until 24 month","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-26T11:47:24.239Z","creation":"2025-02-19T04:59:40.471Z"},"accession":"S-EPMC9839494","cross_references":{"pubmed":["36251401"],"doi":["10.1002/ajh.26768"]}}